The abstract is read at the publisher; the summary is JClub's.
In a cohort of youths aged 12–21 years with overweight or obesity, glucagon-like peptide-1 receptor agonist therapy is explored for its association with biliary outcomes.
- Why it matters: Biliary events are a key safety concern for GLP-1 receptor agonist use in young people, but risk patterns in adolescents and young adults remain unclear.
- What they did: This cohort study followed youths aged 12–21 years diagnosed with overweight or obesity and assessed biliary outcomes in relation to glucagon-like peptide-1 receptor agonist therapy.
- The result: The study characterizes biliary outcomes linked to GLP-1 receptor agonist use in this age group, informing safety considerations for adolescents and young adults with overweight or obesity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.